Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer.
In this study, we assessed the efficacy and feasibility of a 5-FU, MMC and cisplatin combination in patients with advanced or recurrent gastric cancer. 5-FU was administered at a dose of 360 mg/m2 on days 1 through 5 and days 8 through 12. CDDP was administered at a dose of 7 mg/m2 on days 1 through 5 and days 8 through 12. MMC was given at a dose of 13 mg/m2 on day 1. Twenty-seven patients with non-resectable or recurrent gastric cancer were entered. The most common toxicity was leukopenia. Nausea/vomiting was generally mild and no patient suffered severe diarrhea, mucositis or renal insufficiency. While a complete response was not observed, 13 patients showed a PR giving an overall response rate of 48.1% (95%CI, 28.0 to 68.3%). Our regimen may have advantages in terms of reduced toxicity with moderate efficacy that is comparable with results using the ECF regimen.